Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6252953

N#Cc1c(-c2ccccc2F)cc(-c2ccc(O)c(O)c2)nc1N.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IL4 P05112 1/20 0.58
KDM4E B2RXH2 3/20 0.58
HPGD P15428 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
ADORA1 P30542 6/20 0.50
ADORA2A P29274 5/20 0.50
PIM1 P11309 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
IKBKB O14920 6/20 0.48
BLM P54132 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6251702 0.92 IL4 (0.68) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
Trifluoroacetic Acid SCHEMBL6249891 0.87 IKBKB (0.60) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL6252955 0.84 KDM4E (0.54) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL31695325 0.82 IL4 (0.72) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL6253647 0.81 IKBKB (0.65) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL6254004 0.80 ADORA1 (0.72) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL6251132 0.80 KDM4E (0.77) KDM4EHPGDSMN1; SMN2ALDH1A1GLA
Trifluoroacetic Acid SCHEMBL6256893 0.80 ADORA1 (0.62) KDM4EHPGDSMN1; SMN2ALDH1A1GLA
SCHEMBL6255803 0.78 KDM4E (0.67) IL4KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL6249893 0.78 KDM4E (0.56) IL4KDM4EHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569645-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS Pharmacia Corporation (US) 2005-09-07 EP disclosed
EP-1569932-A1 AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Pharmacia Corporation (US) 2005-09-07 EP disclosed
US-20040142978-A1 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION (US) 2004-07-22 US disclosed
WO-2004055015-A1 AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 PHARMACIA CORPORATION (US) 2004-07-01 WO disclosed
WO-2004054505-A2 METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS PHARMACIA CORPORATION (US) 2004-07-01 WO disclosed
US-20040127519-A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127519-A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors MAPKAPK2, MAP2K2, MAP3K2 IL4 4172/4885KDM4E 1736/4885HPGD 1207/4885
US-20040142978-A1 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 MAP4K2, MAP3K20, MAPKAPK2 IL4 3669/4885KDM4E 1684/4885HPGD 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.